<DOC>
	<DOCNO>NCT00049673</DOCNO>
	<brief_summary>RATIONALE : Thalidomide may stop growth multiple myeloma stop blood flow tumor . It yet know whether combine thalidomide prednisone give autologous stem cell transplantation may effective treat multiple myeloma . PURPOSE : This randomized phase III trial study thalidomide prednisone see well work compare observation treat patient undergone stem cell transplantation multiple myeloma .</brief_summary>
	<brief_title>Thalidomide Prednisone After Autologous Stem Cell Transplantation Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient multiple myeloma treat thalidomide prednisone maintenance therapy vs observation alone autologous stem cell transplantation . - Compare progression-free survival patient treat regimen . - Compare quality life patient treat regimen . - Compare toxic effect regimens patient . - Compare objective venous thromboembolism rate symptomatic patient treat regimen . OUTLINE : This randomize , non-blinded , multicenter study . Patients stratify accord treatment center , age ( 60 vs 60 ) , response prior transplantation ( complete v incomplete ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral thalidomide daily oral prednisone every day 4 year absence disease progression unacceptable toxicity . - Arm II : Patients undergo observation . For arm , patient assess ( include quality life ) regularly throughout treatment/observation period : baseline , every 2 month 6 month , every 3 month 4 year , annually thereafter . After treatment/observation period , patient follow annually.. PROJECTED ACCRUAL : A total 324 patient accrue study within 3.5 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm multiple myeloma evidence one following : Biopsy osteolytic lesion soft tissue tumor compose plasma cell Bone marrow aspirate and/or biopsy demonstrate least 10 % plasmacytosis Bone marrow le 10 % plasma cell least 1 bony lesion meet Mprotein criterion Detectable serum Mcomponent IgG , IgA , IgD , IgE initial diagnosis OR Urinary excretion light chain ( Bence Jones ) protein least 1.0 gm/24 hr light chain disease ( urine Mprotein ) present initial diagnosis Previously treat autologous stem cell transplantation highdose melphalan ( 200 mg/m^2 ) within past 60100 day Received transplantation within 1 year begin initial chemotherapy multiple myeloma No evidence disease progression PATIENT CHARACTERISTICS : Age 16 Performance status ECOG 02 Life expectancy At least 6 month Hematopoietic No prior hereditary hypercoaguable disorder Granulocyte count least 1,000/mm^3 Platelet count least 75,000/mm^3 Hepatic Bilirubin great 2 time upper limit normal ( ULN ) AST and/or ALT great 2 time ULN Alkaline phosphatase great 2 time ULN Renal Creatinine great 3 time ULN Cardiovascular No prior spontaneous deep vein thrombosis within past 5 year Catheterassociated thrombus allow No uncontrolled hypertension Pulmonary No prior pulmonary embolism within past 5 year Other No prior concurrent malignancy except adequately treat squamous cell basal cell skin cancer carcinoma situ cervix cancer treat 5 year prior study entry presume cure No prior gastric ulceration bleed within past 5 year No prior document lupus anticoagulant antiphospholipid antibody Not pregnant nursing Negative pregnancy test Fertile female patient must use 2 effective method contraception 1 month prior , , 1 month study participation Male patient must use effective barrier contraception 1 month study participation No avascular necrosis hip shoulder No grade 2 great peripheral neuropathy cause symptomatic dysfunction ( vincristineinduced sensory symptom allow ) No diabetes endorgan damage define : Documented diabetic neuropathy Retinal vascular proliferation require treatment Cardiovascular disease require active therapy Willing complete quality life questionnaires Employment prohibit use sedatives No major medical illness condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics No prior double autologous allogeneic hematopoietic stem cell transplantation No prior thalidomide Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No concurrent anticancer therapy No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>